Details for Patent: 7,799,336

Which drugs does patent 7,799,336 protect, and when does it expire?

Patent 7,799,336 protects DURYSTA and is included in one NDA.

This patent has eighty-two patent family members in twenty-three countries.

Summary for Patent: 7,799,336

Title:	Hypotensive lipid-containing biodegradable intraocular implants and related methods
Abstract:	Biocompatible intraocular implants include a prostamide component and a biodegradable polymer that is effective in facilitating release of the prostamide component into an eye for an extended period of time. The prostamide component may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat or reduce a at least one symptom of an ocular condition, such as glaucoma.
Inventor(s):	Hughes; Patrick M. (Alsio Viejo, CA)
Assignee:	Allergan, Inc. (Irvine, CA)
Application Number:	10/837,260
Patent Claim Types: see list of patent claims	Compound; Device;

Drugs Protected by US Patent 7,799,336

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Abbvie	DURYSTA	bimatoprost	IMPLANT;OPHTHALMIC	211911-001	Mar 4, 2020		RX	Yes	Yes			Y

International Family Members for US Patent 7,799,336

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	E397934
Australia	2005244203
Australia	2007223057
Australia	2011239642
Brazil	112012026535
Brazil	PI0510311
Brazil	PI0708622